G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An analysis of outcomes in Japanese patients who had undergone curative surgical resection for stage I-III CRC revealed a significantly worse 3-year RFS rate in patients with KRAS G12C than in patients with KRASwt (33.3% vs. 81.9%; HR 6.57 [95% CI: 1.90, 17.7; P < .001]).68”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.07.010 · Cited by 361
Watanabe, T., Yoshino, T., Uetake, H., Yamazaki, K., Ishiguro, M., Kurokawa, T., Saijo, N., Ohashi, Y., & Sugihara, K. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt062 · Cited by 46
Research works printed but not linked: 17
- McCubrey JA, Steelman LS, Chappell WH et al (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263–1284 · DOI · Paper page
- Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell. 61:759–767 · DOI · Paper page
- Barbacid M (1987) ras genes. Annu Rev Biochem 56:779–827 · DOI · Paper page
- Al-Mulla F, Milner-White EJ, Going JJ, Birnie GD (1999) Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J Pathol 187:433–438 · DOI · Paper page
- Guerrero S, Casanova I, Farre´ L, Mazo A, Capella` G, Mangues R (2000) K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60:6750–6756
- Smith G, Bounds R, Wolf H, Steele RJC, Carey FA, Wolf CR (2010) Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours—implications for personalised cancer medicine. Br J Cancer 102:693–703 · DOI · Paper page
- Taniguchi H, Yamazaki K, Yoshino T, Muro K, Yatabe Y, Watanabe T, Ebi H, Ochiai A, Baba E, Tsuchihara K (2015) Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients. Cancer Sci 106:324–327 · DOI · Paper page
- Amin MB, Edge S, Greene F et al (2017) AJCC cancer staging manual, 8th edn. Springer, New York · DOI · Paper page
- Yokota T, Ura T, Shibata N et al (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104:856–862 · DOI · Paper page
- Yoon HH, Tougeron D, Shi Q et al (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033–3043 · DOI · Paper page
- Imamura Y, Morikawa T, Liao X et al (2012) Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 18:4753–4763 · DOI · Paper page
- Ogura T, Kakuta M, Yatsuoka T et al (2014) Clinicopathlogical characteristics and prognostic impact of colorectal cancers with NRAS mutations. Oncol Rep 32:50–56 · DOI
- John J, Frech M, Wittinghofer A (1988) Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation reaction. J Biol Chem 263:11792–11799 · DOI · Paper page
- John J, Schlichting I, Schiltz E, Rosch P, Wittinghofer A (1989) C-terminal truncation of p21H preserves crucial kinetic and structural properties. J Biol Chem 264:13086–13092 · DOI · Paper page
- Bollag G, McCormick F (1995) Intrinsic and GTPase-activating protein-stimulated Ras GTPase assays. Methods Enzymol 255:161–170 · DOI
- Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD (1984) Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 312:71–75 · DOI · Paper page
- Goody RS, Pai EF, Schlichting I et al (1992) Studies on the structure and mechanism of H-ras p21. Philos Trans R Soc Lond Ser B Biol Sci 336:3–10 · DOI · Paper page
Cited by
KRAS: From undruggable to a druggable Cancer Target
Uprety, D., & Adjei, A. A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102070 · Cited by 271
A Comparative Analysis of Individual RAS Mutations in Cancer Biology
Muñoz-Maldonado, C., Zimmer, Y., & Medová, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01088 · Cited by 254
Mechanisms of Resistance to KRASG12C-Targeted Therapy
Akhave, N. S., Biter, A. B., & Hong, D. S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1616 · Cited by 156
Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
Koulouridi, A., Karagianni, M., Messaritakis, I., Sfakianaki, M., Voutsina, A., Trypaki, M., Bachlitzanaki, M., Koustas, E., Karamouzis, M. V., Ntavatzikos, A., et al. (2022) · Cancers · doi:10.3390/cancers14143320 · Cited by 63
Strickler, J. H., Yoshino, T., Stevinson, K., Eichinger, C. S., Giannopoulou, C., Rehn, M., & Modest, D. P. (2023) · The Oncologist · doi:10.1093/oncolo/oyad138 · Cited by 54
Metadata
- Authors
- Hayama, T., Hashiguchi, Y., Okamoto, K., Okada, Y., Ono, K., Shimada, R., Ozawa, T., Toyoda, T., Tsuchiya, T., Iinuma, H., Nozawa, K., & Matsuda, K.
- Venue
- International Journal of Colorectal Disease
- Published
- 2019-07-15
- Volume
- 34
- Issue
- 8
- Pages
- 1491-1496
- ISSN
- 0179-1958
- 1432-1262
- Cited by
- 62
- References
- 3
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.